Cocrystal Pharma (COCP) Total Current Liabilities (2010 - 2026)

Cocrystal Pharma (COCP) has 16 years of Total Current Liabilities data on file, last reported at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 15.43% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (up 15.43% YoY), and the FY2025 full-year result was $2.2 million, down 8.98% from the prior year.
• Total Current Liabilities advanced to $2.2 million in Q1 2026, from $2.2 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $3.3 million in Q4 2023 to a low of $1.2 million in Q4 2022.
• A 5-year average of $2.1 million and a median of $1.9 million in 2024 frame the typical range for Total Current Liabilities.
• Peak annual rise in Total Current Liabilities reached 168.26% in 2023, while the deepest fall reached 43.58% in 2023.
• Tracing COCP's Total Current Liabilities over 5 years: stood at $1.2 million in 2022, then surged by 168.26% to $3.3 million in 2023, then fell by 25.57% to $2.4 million in 2024, then decreased by 8.98% to $2.2 million in 2025, then gained by 0.86% to $2.2 million in 2026.
• Business Quant data shows COCP's Total Current Liabilities at $2.2 million in Q1 2026, $2.2 million in Q4 2025, and $1.5 million in Q3 2025.